



## ABSTRACT SUBMISSION TERMS AND CONDITIONS 2020

### Introduction

The abstract submission terms and conditions of the EHA Annual Congress are intended to provide clear instructions before submitting an abstract. You are kindly requested to carefully read the guidelines stated below.

The EHA and its Scientific Program Committee (SPC) and Advisory Board (SPC-AB) maintain the right to reject any abstract that does not meet below requirements or is in violation of them.

### Table of Contents

<b>Deadline abstract submission .....</b>	<b>2</b>
<b>General abstract guidelines.....</b>	<b>2</b>
<b>Abstract review, selection and publication .....</b>	<b>3</b>
General comments.....	3
Procedure abstract review & selection.....	3
Abstract topics .....	4
<b>EHA Travel Grants.....</b>	<b>5</b>
Application criteria.....	5
How to apply for a travel grant.....	5
<b>How to submit an abstract.....</b>	<b>6</b>
Step by step guide.....	6
Abstract format information.....	7
<b>EHA Copyrights &amp; Permissions .....</b>	<b>8</b>
<b>Translation Rights.....</b>	<b>9</b>



### **Deadline abstract submission**

The deadline for abstract submission is March 1, 2020, submissions received after this deadline will not be considered.

### **General abstract guidelines**

1. The Scientific Program Committee (SPC) encourages the submission of original scientific material unpublished at the time of the abstract submission deadline:
  - a. Abstracts submitted to regional or national hematology meetings can be submitted to the EHA Congress for inclusion in the program;
  - b. Abstracts previously submitted to large international meetings which are organized in the same period as the EHA Congress (May – July) are allowed to be submitted to the Congress. Examples of international meetings are the American Society of Clinical Oncology (ASCO), International Society of Thrombosis and Haemostasis (ISTH) and the International Congress on Malignant Lymphomas (ICML).
  - c. Abstracts presented at a large international meeting in the preceding year, may also be submitted provided a clear indication about significant novel or updated information included in the appropriate abstract submission field.
2. The SPC retains the right to allocate abstracts containing previously submitted or presented data as they see fit.
3. Authors of submitted abstracts irrevocably and unconditionally transfer, which transfer EHA hereby accepts, any and all copyright to the abstract to EHA, the European Hematology Association. In accordance with the Abstract Submission Terms & Conditions and after the abstract has been published, either in print or online, authors retain the right to:
  - reprint the article in print collections of the author's own writing;
  - present the work orally in its entirety;
  - use the article in theses and/or dissertation;
  - reproduce the article for use in courses he/she is teaching and to the extent that he/she is employed by an academic institution, the institution may also reproduce the article for course teaching;
  - distribute photocopies of the article to colleagues, but only for non-commercial purposes;
  - reuse figures and tables created by the author in future works; and post a copy of the article on my personal website, departmental website, and/or the university intranet. A hyperlink to the article / publication on the EHA website must be included.EHA will utilize the copyright in a reasonable way, related to the publishing, republishing and transfer of copyrights of submitted abstracts.
4. Submitted abstracts are considered embargoed from the time of submission.
5. Interim analysis of a prospective randomized clinical trial will usually be considered only if it is performed as planned in the original protocol and is statistically valid.
6. Case reports are generally not accepted unless they bring significant and novel biological information.
7. The abstract title and text may not contain trade names. The SPC reserves the right to replace trade names in accepted abstracts.
8. In clinical studies, please state whether informed consent was obtained.
9. If off label use of drugs was involved, please state this clearly.
10. Do not submit the same study in multiple abstracts. Abstracts that appear as more than one version of a single study will be rejected.
11. Similarly, do not submit a copy or close copy of an abstract under more than 1 category. Abstracts that appear to be submitted multiple times under different categories will be rejected.



12. Abstracts should be submitted in clear (American) English to allow the reviewers to focus on the scientific content of the abstract. Non-English speaking authors are encouraged to have their abstract checked for grammar and spelling.
13. The SPC assumes all presenting authors have proficiency in English, thus are able to present and respond to questions. Otherwise authors are encouraged to choose poster presentation as a preference.

### **Abstract review, selection and publication**

#### General comments

- An international panel of experts will review the abstracts.
- Each abstract will be reviewed by at least five different reviewers.
- Abstracts may be selected for
  - oral presentation
  - poster presentation
  - publication only
  - rejection.
- Only the submitting author will receive a confirmation of acceptance for oral presentation, poster presentation, publication only or a notice of rejection, by e-mail before April 24, 2020.
- The best abstracts will be selected for an oral presentation in the Presidential Symposium.
- Authors of abstracts selected for an oral presentation will be informed about the type and date of the session and presentation guidelines will be provided.
- Poster presenters will be informed about the date of the poster session and will receive guidelines for their presentation.
- All accepted abstracts will be published in the abstract book.
- Withdrawal policy: If authors wish to withdraw their abstracts from presentation or publication they are requested to send a letter via e-mail to the congress secretariat before May 1, 2020. Consequently, the abstract will not be presented nor published.

#### **Procedure abstract review & selection**

All abstracts submitted before March 1, will be reviewed by an international panel of experts (representing all subspecialties and a large number of countries). The authors assign their abstracts to one of currently 36 topics and for each topic 6 reviewers are asked to score all abstracts in that category. Within 10 days after the closure of the abstract submission, the reviewers (a total of 250 - 300 experts) are requested to read and score each abstract in their category based on the scientific merit. If fewer than 4 reviewers return their evaluation for a given topic, the SPC chair recruits additional reviewers in that field to meet this minimal requirement.

The scoring system is a scale ranging from 1 to 8, with a qualitative explanation of each grade. Once all abstracts have been reviewed, the scores are averaged.

A coordinating reviewer per abstract topic will be installed with the goal of identifying discrepancies in the scores, organizing the discussion of abstracts and the validation of merit abstracts. Following the review week, teleconferences will be scheduled between the coordinating reviewer and the reviewers of each topic, to review the scores and select the abstracts for the program.



The outcome of each teleconference is reviewed during a meeting in March 2020 by the Scientific Program Committee (23 members), Advisory Board (27 members) and coordinating reviewers if not part of the SPC or AB. During the meeting the oral sessions will be made and the abstract program will be finalized.

### Abstract Topics

1. Acute lymphoblastic leukemia - Biology & Translational Research
2. Acute lymphoblastic leukemia - Clinical
3. Acute myeloid leukemia - Biology & Translational Research
4. Acute myeloid leukemia - Clinical
5. Chronic lymphocytic leukemia and related disorders - Biology & Translational Research
6. Chronic lymphocytic leukemia and related disorders - Clinical
7. Chronic myeloid leukemia - Biology & Translational Research
8. Chronic myeloid leukemia - Clinical
9. Myelodysplastic syndromes - Biology & Translational Research
10. Myelodysplastic syndromes - Clinical
11. Bone marrow failure syndromes incl. PNH - Biology & Translational Research
12. Bone marrow failure syndromes incl. PNH - Clinical
13. Myeloma and other monoclonal gammopathies - Biology & Translational Research
14. Myeloma and other monoclonal gammopathies - Clinical
15. Myeloproliferative neoplasms - Biology & Translational Research
16. Myeloproliferative neoplasms - Clinical
17. Hodgkin lymphoma - Clinical
18. Indolent and mantle-cell non-Hodgkin lymphoma - Clinical
19. Aggressive Non-Hodgkin lymphoma - Clinical
20. Lymphoma Biology & Translational Research
21. Stem cell transplantation - Experimental
22. Stem cell transplantation - Clinical
23. Hematopoiesis, stem cells and microenvironment
24. Gene therapy, cellular immunotherapy and vaccination - Biology & Translational Research
25. Gene therapy, cellular immunotherapy and vaccination - Clinical
26. Sickle cell disease
27. Thalassemias
28. Enzymopathies, membranopathies and other anemias
29. Iron metabolism, deficiency and overload
30. Infectious diseases
31. Transfusion medicine
32. Platelets disorders
33. Bleeding disorders (congenital and acquired)
34. Thrombosis and vascular biology - Biology & Translational Research
35. Quality of life, palliative & supportive care, ethics and health economics



### **EHA Travel Grants**

Travel grants, consisting of € 500 and free registration for the Congress, will be available for investigators with accepted abstracts. Travel grants are specially intended to support young investigators; therefore, applicants should be 36 years or younger of age.

Several travel grants have been reserved for abstract authors from countries with lower- and lower/middle-income economies.

The SPC will decide, according to the scores of the abstracts, which abstract receives a travel grant. This will be announced to the submitting author by e-mail before April 24, 2020.

### **Application criteria**

Authors wishing to be considered for a grant should be:

- the submitting, first and presenting author of a submitted abstract
- a junior member of EHA (main criterion: 36 years or younger of age)
- membership fee has been paid before March 1, 2020.

### **How to apply for a travel grant**

Complete the online travel grant application form on the EHA website. The deadline for travel grant applications, supporting documents and additional information is March 1, 2020 (in parallel with the deadline for abstract submission). Only complete online applications, meeting all the above criteria, will be considered.

Should you have any questions or queries, contact us at [Travelgrants@ehaweb.org](mailto:Travelgrants@ehaweb.org).



## How to submit an abstract

For access to the abstract form, you will first require a login name and password. You may choose your own login name and password. If you have already used MCI's B-Com program before for EHA or another congress, you can use these login details.

### Step by step guide:

1. **Contact information** - Fill in all fields marked with (\*).

Note: the person submitting will be who is contacted regarding an abstract status when announced as of April 1<sup>st</sup>.

2. **Submission type selection** - Read and accept the declaration, Click next.
3. **Abstract Classification** - fill in all fields marked with (\*).
4. **Authors** - Please follow instructions for all author and co-author details here. Note that the first entry in the table is pre-filled with the submitter's details. This entry can be removed by clicking on (X).
5. **Abstract body** - Here you enter your abstract and upload an image/figure if you have this (please note instructions on the right side of the page, and for image information this is beneath the grey upload box).
6. **Abstract Preview** - You will then be able to preview your abstract. If your abstract has met all requirements you will see a grey box "set as final submission". You click this box only when you are happy with your abstract to finally submit for review.

If your abstract does not meet the requirements you will be asked to save as a draft. You can then login in as often as you wish before the deadline to amend until you are happy with it and it meets all requirements.

7. **Confirmation** - Once you click "set as final submission" your abstract is set for review. However, before the submission deadline (March 1, 2020; 23:59 CET), you will be able to login again and edit your abstract. Note that you will no longer be able to edit your abstract after the submission deadline.

After submitting your abstract successfully, you and the co-authors will receive a confirmation of the submission by e-mail.



### Abstract format information

General format:

- Character count: 3600 including spaces and punctuation
- Title count – 200 characters including spaces
- Title case: Upper
- Max number of lines: 45
- Max number of keywords: 4

All abstract body content sections are mandatory (e.g. background, aims, methods, results, conclusion/summary.)

### Image sizing guideline:

Image Options		
	Min	Max
Width (in px)	1	500
Height (in px)	1	500
Size (in KB)	1	1,000
DPI	1	300

Only JPG, GIF or PNG file can be uploaded.

- 1 image can be submitted
- Table can be used
- Image is not included in the Character count

### Author affiliation guide:

- Department
- Institution - Mandatory
- City - Mandatory
- Country - Mandatory

Only 1 presenting author

1 submitting author – (this person is who is contacted with regards to feedback of their abstract)

No co-author count (unlimited)

### Contact information

Should you require further help with your abstract submission or have any questions, please contact the congress secretariat:

MCI Amsterdam

Tel: +31 (0)20 570 96 00

Fax: +31 (0)20 673 73 06

E-mail: [aha@mci-group.com](mailto:aha@mci-group.com)



## **EHA Copyrights & Permissions**

Material published in “Hematology Education: the education program for the annual congress of the European Hematology Association” and the Annual Congress Abstract Book are covered by copyright. All rights reserved. No part of the publication may be reproduced (see exception below), stored in a retrieval system, translated, or transmitted in any form or by any means now or hereafter known, electronic or mechanical, without permission in writing from the publisher, the European Hematology Association (EHA).

### **Republication Requests**

#### **Authors reusing their own material**

Authors have permission to do the following after their article or abstract has been published, either in print or online.

- Reprint the article in print collections of the author's own writing.
- Present the work orally in its entirety.
- Use the article in theses and/or dissertation.
- Reproduce the article for use in courses the author is teaching. If the author is employed by an academic institution, that institution may also reproduce the article for course teaching.
- Distribute photocopies of the article to colleagues, but only for noncommercial purposes.
- Reuse figures and tables created by the author in future works.
- Post a copy of the article on the author's personal website, departmental website, and/or the university intranet. A hyperlink to the article / publication on the EHA website must be included.

The author must include the following citation when citing material:

Hematology Education:

Title, Author(s), Hematology Education, Year, beginning page number-ending page number.

Abstract Book:

Title, Author(s), Journal Year; Volume (Supplement nr): Page. Abstract nr XXX.

Authors reusing their own material in the above ways do not need to contact EHA for permission. For all other uses, the author must request permission from EHA by e-mailing [info@ehaweb.org](mailto:info@ehaweb.org).

#### **All others wishing to use material**

Written permission to republish any parts of works owned by EHA must be obtained prior to usage. To do so, please request permission from EHA by e-mailing [info@ehaweb.org](mailto:info@ehaweb.org).



## Translation Rights

EHA permits Hematology Education articles and abstracts to be translated into foreign languages, which can be reprinted for distribution. Please see our terms and conditions below.

- Nothing may be added to or deleted from the original text, figures, references or editorial notes.
- No product advertising or company logos will be permitted in foreign language reprints. No content that was not originally published as part of the article may be printed together with the article as one printed piece. A tracking number for inventory purposes may be printed on the back of the reprints, but nowhere else.
- If any attachments, such as product information, are to be distributed with the reprinted article, the following methods only may be used:
  - Insert product information into reprint as a loose leaf
  - Staple product information to reprint after the translated reprint has been bound
- EHA reserves the right to inspect the content and the packaging for the foreign language edition of the articles and abstracts prior to distribution.
- The following disclaimer must be included on the back of all translated reprints. The disclaimer must appear in English, as well as in the language of the reprint.  
“© European Hematology Association. Reprinted with permission from the European Hematology Association, which does not endorse any particular uses of this document. The European Hematology Association is not responsible for the completeness or the accuracy of the translation.

For further information, or to request permission to translate an article, please contact EHA by e-mailing [info@ehaweb.org](mailto:info@ehaweb.org).

## Reprints

### **Author and commercial reprints**

Authors wishing to order reprints should contact EHA by e-mailing [info@ehaweb.org](mailto:info@ehaweb.org).